company background image
CADL

Candel Therapeutics NasdaqGM:CADL Stock Report

Last Price

US$1.80

Market Cap

US$52.0m

7D

6.5%

1Y

-82.0%

Updated

01 Dec, 2022

Data

Company Financials +
CADL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CADL Stock Overview

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.

Candel Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Candel Therapeutics
Historical stock prices
Current Share PriceUS$1.80
52 Week HighUS$10.22
52 Week LowUS$1.47
Beta0
1 Month Change-5.26%
3 Month Change-44.95%
1 Year Change-81.96%
3 Year Changen/a
5 Year Changen/a
Change since IPO-74.29%

Recent News & Updates

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Sep 15

Recent updates

Shareholder Returns

CADLUS BiotechsUS Market
7D6.5%2.7%1.4%
1Y-82.0%-10.3%-16.1%

Return vs Industry: CADL underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: CADL underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is CADL's price volatile compared to industry and market?
CADL volatility
CADL Average Weekly Movement15.1%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: CADL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: CADL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200365Paul-Peter Takhttps://www.candeltx.com

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.

Candel Therapeutics, Inc. Fundamentals Summary

How do Candel Therapeutics's earnings and revenue compare to its market cap?
CADL fundamental statistics
Market CapUS$52.01m
Earnings (TTM)-US$12.11m
Revenue (TTM)US$125.00k

416.7x

P/S Ratio

-4.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CADL income statement (TTM)
RevenueUS$125.00k
Cost of RevenueUS$4.49m
Gross Profit-US$4.37m
Other ExpensesUS$7.75m
Earnings-US$12.11m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.42
Gross Margin-3,492.80%
Net Profit Margin-9,692.00%
Debt/Equity Ratio39.8%

How did CADL perform over the long term?

See historical performance and comparison